Search Results

Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis).

• Authors : Gargiulo L; Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.; Department of Biomedical Sciences, Humanitas University, Milan, Italy.

Subjects: Biological Products*/Biological Products*/Biological Products*/therapeutic use ; Psoriasis*/Psoriasis*/Psoriasis*/drug therapy; Humans

• Source: Frontiers in immunology [Front Immunol] 2024 Jan 11; Vol. 14, pp. 1341708. Date of Electronic Publication: 2024 Jan 11 (Print Publication: 2023).Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet

Record details

Comparing clinical trial population representativeness to real-world users of 17 biologics approved for immune-mediated inflammatory diseases: An external validity analysis of 66,639 biologic users from the Italian VALORE project.

• Authors : Ingrasciotta Y; University of Verona, Department of Diagnostics and Public Health, Verona, Italy.; Spini A

Subjects: Biological Products*/Biological Products*/Biological Products*/adverse effects ; Psoriasis*/Psoriasis*/Psoriasis*/drug therapy; Adult

• Source: Pharmacological research [Pharmacol Res] 2024 Feb; Vol. 200, pp. 107074. Date of Electronic Publication: 2024 Jan 15.Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8907422 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study).

• Authors : Chiricozzi A; U.O.C. di Dermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.; Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.

Subjects: Quality of Life* ; Psoriasis*/Psoriasis*/Psoriasis*/drug therapy; Humans

• Source: The Journal of dermatological treatment [J Dermatolog Treat] 2023 Dec; Vol. 34 (1), pp. 2246606.Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print Cited Medium: Internet ISSN: 1471-1753

Record details

Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy.

• Authors : Dastoli S; Department of Health Sciences, Magna Graecia University, Catanzaro, Italy.; Passante M

Subjects: Antibodies, Monoclonal*/Antibodies, Monoclonal*/Antibodies, Monoclonal*/adverse effects ; Psoriasis*/Psoriasis*/Psoriasis*/drug therapy ; Psoriasis*/Psoriasis*/Psoriasis*/chemically induced

• Source: The Journal of dermatological treatment [J Dermatolog Treat] 2023 Dec; Vol. 34 (1), pp. 2200868.Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print Cited Medium: Internet ISSN: 1471-1753

Record details

Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis).

• Authors : Gargiulo L; Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy.; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.

Subjects: Psoriasis*/Psoriasis*/Psoriasis*/drug therapy ; Psoriasis*/Psoriasis*/Psoriasis*/pathology ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/administration & dosage

• Source: The Journal of dermatological treatment [J Dermatolog Treat] 2024 Dec; Vol. 35 (1), pp. 2350760. Date of Electronic Publication: 2024 May 07.Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Efficacy and safety of dimethylfumarate in elderly psoriasis patients: a multicentric Italian study.

• Authors : Ricceri F; Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy.; Bardazzi F

Subjects: Lymphopenia* ; Psoriasis*/Psoriasis*/Psoriasis*/drug therapy; Aged

• Source: The Journal of dermatological treatment [J Dermatolog Treat] 2022 Jun; Vol. 33 (4), pp. 2000-2003. Date of Electronic Publication: 2021 Aug 11.Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

2-Year Experience with Risankizumab in the Treatment of Plaque Psoriasis in Lazio Region, Italy.

• Authors : Caldarola, Giacomo^1,2 (AUTHOR); De Luca, Eleonora^1,2 (AUTHOR); Bavetta, Mauro³ (AUTHOR)

• Source: Dermatologic Therapy. 9/19/2023, p1-6. 6p.

Record details

Determinants of patient and physician treatment satisfaction in moderate-to-severe psoriasis: a multinational survey of psoriasis patients.

• Authors : Teeple A; Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, USA;. .

Subjects: Patient Satisfaction* ; Personal Satisfaction* ; Surveys and Questionnaires*

• Source: Dermatology online journal [Dermatol Online J] 2021 Oct 15; Vol. 27 (10). Date of Electronic Publication: 2021 Oct 15.Publisher: University of California, Davis Country of Publication: United States NLM ID: 9610776 Publication Model: Electronic Cited Medium: Internet

Record details

Choice of Systemic Drugs for the Management of Moderate-to-severe Psoriasis: A Cross-country Comparison Based on National Health Insurance Data.

• Authors : Sbidian E; Department of Dermatology, Hôpital Henri-Mondor, 51, av du Maréchal de Lattre de Tassigny, FR-94010 Créteil Cedex, France. E-mail: .; Mezzarobba M

Subjects: Dermatologic Agents* ; Pharmaceutical Preparations* ; Psoriasis*/Psoriasis*/Psoriasis*/diagnosis

• Source: Acta dermato-venereologica [Acta Derm Venereol] 2021 Jun 22; Vol. 101 (6), pp. adv00473. Date of Electronic Publication: 2021 Jun 22.Publisher: Society for the Publication of Acta Dermato-Venereologica Country of Publication: Sweden NLM ID: 0370310 Publication Model: Electronic Cited

Record details

Impact of Functional Polymorphisms on Drug Survival of Biological Therapies in Patients with Moderate-to-Severe Psoriasis.

• Authors : Membrive-Jiménez, Cristina¹ (AUTHOR) ; Pérez-Ramírez, Cristina² (AUTHOR) ; Arias-Santiago, Salvador³ (AUTHOR)

Subjects: *BIOTHERAPY; *TUMOR necrosis factors; *PSORIASISITALY; SPAIN

• Source: International Journal of Molecular Sciences. May2023, Vol. 24 Issue 10, p8703. 18p.

Record details